Recreational ketamine use and its impact on health
DOI:
https://doi.org/10.12775/JEHS.2024.68.55185Keywords
ketamine, recreational drugs, acute toxicity, chronic toxicity, drug abuseAbstract
Ketamine, also known as 2-(2-chlorophenyl)-2-(methylamino)-cyclohexanone, is a dissociative anesthetic that has gained popularity as a recreational substance among young people, especially in nightclubs and at parties. It acts as a noncompetitive NMDA receptor antagonist, inducing a dissociative state that manifests as catalepsy, unconsciousness and amnesia. Recreational use of ketamine and the number of illicit seizures of ketamine have increased in recent years, prompting a review of current evidence on its toxicity. Recreational ketamine use is associated with a number of toxic effects, both acute and chronic. Predominant among the acute effects are psychotic symptoms, hallucinations and aggression, which can lead to serious injuries. Chronic ketamine use leads to intractable urological problems and neuropsychiatric problems, Long-term effects also include gastrointestinal problems such as abdominal pain and liver function abnormalities. This review summarizes current evidences on the acute and chronic ketamine toxicity associated with its recreational use.
References
Sachdeva B, Sachdeva P, Ghosh S, Ahmad F, Sinha JK. Ketamine as a therapeutic agent in major depressive disorder and posttraumatic stress disorder: Potential medicinal and deleterious effects. Ibrain. 2023;9(1):90-101. Published 2023 Feb 20. doi:10.1002/ibra.12094
Essential Medicines (EML). WHO Model List of Essential Medicines - 23rd list, 2023. Published July 26, 2023. https://www.who.int/publications/i/item/WHO-MHP-HPS-EML-2023.02
Kalsi SS, Wood DM, Dargan PI. The epidemiology and patterns of acute and chronic toxicity associated with recreational ketamine use. Emerg Health Threats J. 2011;4:7107. Published 2011 Apr 15. doi:10.3402/ehtj.v4i0.7107
Sinner B, Graf BM. Ketamine. Handb Exp Pharmacol. 2008;(182):313-333. doi:10.1007/978-3-540-74806-9_15
Lankenau SE, Sanders B. Patterns of ketamine use among young injection drug users. J Psychoactive Drugs. 2007;39(1):21-29. doi:10.1080/02791072.2007.10399861
Palamar JJ, Rutherford C, Keyes KM. Trends in Ketamine Use, Exposures, and Seizures in the United States up to 2019. Am J Public Health. 2021;111(11):2046-2049. doi:10.2105/AJPH.2021.306486
Palamar JJ, Wilkinson ST, Carr TH, Rutherford C, Cottler LB. Trends in Illicit Ketamine Seizures in the US From 2017 to 2022. JAMA Psychiatry. 2023;80(7):750-751. doi:10.1001/jamapsychiatry.2023.1423
Other drugs – the current situation in Europe (European Drug Report 2024) | www.euda.europa.eu. https://www.euda.europa.eu/publications/european-drug-report/2024/other-drugs_en#level-7
DOMINO EF, CHODOFF P, CORSSEN G. PHARMACOLOGIC EFFECTS OF CI-581, A NEW DISSOCIATIVE ANESTHETIC, IN MAN. Clin Pharmacol Ther. 1965;6:279-291. doi:10.1002/cpt196563279
Morgan CJ, Muetzelfeldt L, Curran HV. Ketamine use, cognition and psychological wellbeing: a comparison of frequent, infrequent and ex-users with polydrug and non-using controls. Addiction. 2009;104(1):77-87. doi:10.1111/j.1360-0443.2008.02394.x
Himmelseher S, Pfenninger E. Die klinische Anwendung von S-(+)-Ketamin - eine Standortbestimmung. AINS - Anästhesiologie · Intensivmedizin · Notfallmedizin · Schmerztherapie. 1998;33(12):764-770. doi:10.1055/s-2007-994851
Jansen KL. A review of the nonmedical use of ketamine: use, users and consequences. J Psychoactive Drugs. 2000;32(4):419-433. doi:10.1080/02791072.2000.10400244
Cohen ML, Trevor AJ. On the cerebral accumulation of ketamine and the relationship between metabolism of the drug and its pharmacological effects. J Pharmacol Exp Ther. 1974;189(2):351-358.
Zanos P, Moaddel R, Morris PJ, et al. Ketamine and Ketamine Metabolite Pharmacology: Insights into Therapeutic Mechanisms [published correction appears in Pharmacol Rev. 2018 Oct;70(4):879. doi: 10.1124/pr.116.015198err]. Pharmacol Rev. 2018;70(3):621-660. doi:10.1124/pr.117.015198
Hijazi Y, Boulieu R. Contribution of CYP3A4, CYP2B6, and CYP2C9 isoforms to N-demethylation of ketamine in human liver microsomes. Drug Metab Dispos. 2002;30(7):853-858. doi:10.1124/dmd.30.7.853
Wieber J, Gugler R, Hengstmann JH, Dengler HJ. Pharmacokinetics of ketamine in man. Anaesthesist. 1975;24(6):260-263.
Adamowicz P, Kala M. Urinary excretion rates of ketamine and norketamine following therapeutic ketamine administration: method and detection window considerations. J Anal Toxicol. 2005;29(5):376-382. doi:10.1093/jat/29.5.376
Parkin MC, Turfus SC, Smith NW, et al. Detection of ketamine and its metabolites in urine by ultra high pressure liquid chromatography-tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci. 2008;876(1):137-142. doi:10.1016/j.jchromb.2008.09.036
Green SM, Roback MG, Kennedy RM, Krauss B. Clinical practice guideline for emergency department ketamine dissociative sedation: 2011 update. Ann Emerg Med. 2011 May;57(5):449-61. doi: 10.1016/j.annemergmed.2010.11.030. Epub 2011 Jan 21. PMID: 21256625.
White PF, Schüttler J, Shafer A, Stanski DR, Horai Y, Trevor AJ. Comparative pharmacology of the ketamine isomers. Studies in volunteers. Br J Anaesth. 1985 Feb;57(2):197-203. doi: 10.1093/bja/57.2.197. PMID: 3970799.
Marland S, Ellerton J, Andolfatto G, et al. Ketamine: use in anesthesia. CNS Neuroscience & Therapeutics. 2013;19(6):381-389. doi:10.1111/cns.12072
Zeilhofer HU, Swandulla D, Geisslinger G, Brune K. Differential effects of ketamine enantiomers on NMDA receptor currents in cultured neurons. Eur J Pharmacol. 1992 Mar 17;213(1):155-8. doi: 10.1016/0014-2999(92)90248-3. PMID: 1386806.
Irifune M, Shimizu T, Nomoto M, Fukuda T. Ketamine-induced anesthesia involves the N-methyl-D-aspartate receptor-channel complex in mice. Brain Res. 1992 Nov 20;596(1-2):1-9. doi: 10.1016/0006-8993(92)91525-j. PMID: 1281742.
Smith DJ, Pekoe GM, Martin LL, Coalgate B. The interaction of ketamine with the opiate receptor. Life Sci. 1980 Mar 10;26(10):789-95. doi: 10.1016/0024-3205(80)90285-4. PMID: 6246318.
Schifano F, Corkery J, Deluca P, Oyefeso A, Ghodse AH. Ecstasy (MDMA, MDA, MDEA, MBDB) consumption, seizures, related offences, prices, dosage levels and deaths in the UK (1994-2003). J Psychopharmacol. 2006 May;20(3):456-63. doi: 10.1177/0269881106060147. PMID: 16574720.
Dillon P, Copeland J, Jansen K. Patterns of use and harms associated with non-medical ketamine use. Drug Alcohol Depend. 2003 Jan 24;69(1):23-8. doi: 10.1016/s0376-8716(02)00243-0. PMID: 12536063.
Wolff K, Winstock AR. Ketamine : from medicine to misuse. CNS Drugs. 2006;20(3):199-218. doi: 10.2165/00023210-200620030-00003. PMID: 16529526.
Moore, K. and Measham, F. (2006), "Ketamine use: minimising problems and maximising pleasure", Drugs and Alcohol Today, Vol. 6 No. 3, pp. 29-32. https://doi.org/10.1108/17459265200600047
Fendrich M, Johnson TP. Editors' Introduction to this Special Issue on Club Drug Epidemiology. Subst Use Misuse. 2005;40(9-10):1179-84. doi: 10.1081/JA-200066999. PMID: 16048811.
Barrett SP, Gross SR, Garand I, Pihl RO. Patterns of simultaneous polysubstance use in Canadian rave attendees. Subst Use Misuse. 2005;40(9-10):1525-37. doi: 10.1081/JA-200066866. PMID: 16048831.
Corkery JM, Hung W-C, Claridge H, Goodair C, Copeland CS, Schifano F. Recreational ketamine-related deaths notified to the National Programme on Substance Abuse Deaths, England, 1997–2019. Journal of Psychopharmacology. 2021;35(11):1324-1348. doi:10.1177/02698811211021588
Addiction EMC for D and D. Report on the Risk Assessment of Ketamine in the Framework of the Joint Action on New Synthetic Drugs.; 2002.
Dalgarno PJ, Shewan D. Illicit use of ketamine in Scotland. J Psychoactive Drugs. 1996 Apr-Jun;28(2):191-9. doi: 10.1080/02791072.1996.10524391. PMID: 8811587.
Corazza O, Assi S, Schifano F. From “Special K” to “Special M”: The evolution of the recreational use of ketamine and methoxetamine. CNS Neuroscience & Therapeutics. 2013;19(6):454-460. doi:10.1111/cns.12063
Pomarol-Clotet E, Honey GD, Murray GK, et al. Psychological effects of ketamine in healthy volunteers. Phenomenological study. Br J Psychiatry. 2006;189:173-179. doi:10.1192/bjp.bp.105.015263
2006 Annual report: the state of the drugs problem in Europe | www.euda.europa.eu. https://www.euda.europa.eu/publications/annual-report/2006_en
Beck K, Hindley G, Borgan F, et al. Association of Ketamine With Psychiatric Symptoms and Implications for Its Therapeutic Use and for Understanding Schizophrenia: A Systematic Review and Meta-analysis. JAMA Netw Open. 2020;3(5):e204693. Published 2020 May 1. doi:10.1001/jamanetworkopen.2020.4693
Krystal JH, Karper LP, Seibyl JP, et al. Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses. Arch Gen Psychiatry. 1994;51(3):199-214. doi:10.1001/archpsyc.1994.03950030035004
Moore KA, Kilbane EM, Jones R, Kunsman GW, Levine B, Smith M. Tissue distribution of ketamine in a mixed drug fatality. J Forensic Sci. 1997;42(6):1183-1185.
Weiner AL, Vieira L, McKay CA, Bayer MJ. Ketamine abusers presenting to the emergency department: a case series. J Emerg Med. 2000;18(4):447-451. doi:10.1016/s0736-4679(00)00162-1
Wood DM, Bishop CR, Greene SL, Dargan P. Ketamine-related toxicology presentations to the ED. ResearchGate. Published online January 1, 2008. https://www.researchgate.net/publication/278292954_Ketamine-related_toxicology_presentations_to_the_ED
Chu PS, Ma WK, Wong SC, et al. The destruction of the lower urinary tract by ketamine abuse: a new syndrome?. BJU Int. 2008;102(11):1616-1622. doi:10.1111/j.1464-410X.2008.07920.x
Cottrell A, Warren K, Ayres R, Weinstock P, Kumar V, Gillatt D. The destruction of the lower urinary tract by ketamine abuse: a new syndrome?. BJU Int. 2008;102(9):1178-1179. doi:10.1111/j.1464-410X.2008.08146_2.x
Yeung LY, Rudd JA, Lam WP, Mak YT, Yew DT. Mice are prone to kidney pathology after prolonged ketamine addiction. Toxicol Lett. 2009;191(2-3):275-278. doi:10.1016/j.toxlet.2009.09.006
Mason K, Cottrell AM, Corrigan AG, Gillatt DA, Mitchelmore AE. Ketamine-associated lower urinary tract destruction: a new radiological challenge. Clin Radiol. 2010;65(10):795-800. doi:10.1016/j.crad.2010.05.003
Tsai TH, Cha TL, Lin CM, et al. Ketamine-associated bladder dysfunction. Int J Urol. 2009;16(10):826-829. doi:10.1111/j.1442-2042.2009.02361.x
Shahani R, Streutker C, Dickson B, Stewart RJ. Ketamine-associated ulcerative cystitis: a new clinical entity. Urology. 2007;69(5):810-812. doi:10.1016/j.urology.2007.01.038
Oxley JD, Cottrell AM, Adams S, Gillatt D. Ketamine cystitis as a mimic of carcinoma in situ. Histopathology. 2009;55(6):705-708. doi:10.1111/j.1365-2559.2009.03437.x
Grégoire MC, MacLellan DL, Finley GA. A pediatric case of ketamine-associated cystitis (Letter-to-the-Editor RE: Shahani R, Streutker C, Dickson B, et al: Ketamine-associated ulcerative cystitis: a new clinical entity. Urology 69: 810-812, 2007). Urology. 2008;71(6):1232-1233. doi:10.1016/j.urology.2007.11.141
Selby NM, Anderson J, Bungay P, Chesterton LJ, Kolhe NV. Obstructive nephropathy and kidney injury associated with ketamine abuse. NDT Plus. 2008;1(5):310-312. doi:10.1093/ndtplus/sfn054
Wong SW, Lee KF, Wong J, Ng WW, Cheung YS, Lai PB. Dilated common bile ducts mimicking choledochal cysts in ketamine abusers. Hong Kong Med J. 2009;15(1):53-56.
Ng SH, Lee HK, Chan YC, Lau FL. Dilated common bile ducts in ketamine abusers. Hong Kong Med J. 2009;15(2):157.
Poon TL, Wong KF, Chan MY, et al. Upper gastrointestinal problems in inhalational ketamine abusers. J Dig Dis. 2010;11(2):106-110. doi:10.1111/j.1751-2980.2010.00424.x
Noppers IM, Niesters M, Aarts LPHJ, et al. Drug-induced liver injury following a repeated course of ketamine treatment for chronic pain in CRPS type 1 patients: a report of 3 cases. Pain. 2011;152(9):2173-2178. doi:10.1016/j.pain.2011.03.026
Avra T, Torres J, Felipe Vasudevan K, Samuels EA. "K Cramps," Recurrent Abdominal Pain in a Patient with Chronic Ketamine Use: A Case Report. Clin Pract Cases Emerg Med. 2024;8(3):277-281. doi:10.5811/cpcem.19431
Strous JFM, Weeland CJ, van der Draai FA, Daams JG, Denys D, Lok A, Schoevers RA and Figee M (2022) Brain Changes Associated With Long-Term Ketamine Abuse, A Systematic Review. Front. Neuroanat. 16:795231. doi: 10.3389/fnana.2022.795231
Morgan CJ, Muetzelfeldt L, Curran HV. Consequences of chronic ketamine self-administration upon neurocognitive function and psychological wellbeing: a 1-year longitudinal study [published correction appears in Addiction. 2010 Apr;105(4):766]. Addiction. 2010;105(1):121-133. doi:10.1111/j.1360-0443.2009.02761.x
Jansen KL. Ketamine--can chronic use impair memory?. Int J Addict. 1990;25(2):133-139. doi:10.3109/10826089009056204
Ikonomidou C, Bosch F, Miksa M, et al. Blockade of NMDA receptors and apoptotic neurodegeneration in the developing brain. Science. 1999;283(5398):70-74. doi:10.1126/science.283.5398.70
Zou X, Patterson TA, Divine RL, et al. Prolonged exposure to ketamine increases neurodegeneration in the developing monkey brain. Int J Dev Neurosci. 2009;27(7):727-731. doi:10.1016/j.ijdevneu.2009.06.010
Liao Y, Tang J, Ma M, et al. Frontal white matter abnormalities following chronic ketamine use: a diffusion tensor imaging study. Brain. 2010;133(Pt 7):2115-2122. doi:10.1093/brain/awq131
WHO. International Classification of Diseases (ICD) 10. 2nd ed. Geneva: Author; 2007 [updated 2010 November 5]. Available from: http://apps.who.int/classifications/apps/icd/icd10online/index.htm?gf10.htm_F192.
Marietta MP, White PF, Pudwill CR, Way WL, Trevor AJ. Biodisposition of ketamine in the rat: self-induction of metabolism. J Pharmacol Exp Ther. 1976;196(3):536-544.
Chan WH, Sun WZ, Ueng TH. Induction of rat hepatic cytochrome P-450 by ketamine and its toxicological implications. J Toxicol Environ Health A. 2005;68(17-18):1581-1597. doi:10.1080/15287390590967522
Muetzelfeldt L, Kamboj SK, Rees H, Taylor J, Morgan CJ, Curran HV. Journey through the K-hole: phenomenological aspects of ketamine use. Drug Alcohol Depend. 2008;95(3):219-229. doi:10.1016/j.drugalcdep.2008.01.024
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2024 Jakub Perłowski, Marek Miśkiewicz, Jakub Ptak, Rafał Noga, Victoria Teska, Jagoda Marcinkowska, Adrian Herc, Karolina Koczkodon, Marcelina Sawczuk, Mariusz Krompiewski
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
The periodical offers access to content in the Open Access system under the Creative Commons Attribution-NonCommercial-ShareAlike 4.0
Stats
Number of views and downloads: 202
Number of citations: 0